XML 60 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Revenues $ 78,835 $ 101,657
Cost of products sold 56,214 72,927
Gross profit 22,621 28,730
Operating expenses:    
Research and development (including $223 and $260 of amortization of intangible assets, respectively) 5,859 7,216
Selling, general, and administrative (including $179 and $237 of amortization of intangible assets, respectively) 17,386 21,628
Total operating expenses 23,245 28,844
Operating loss (624) (114)
Other income (expense):    
Interest income 39 4
Interest expense (238) (440)
Miscellaneous (26) (24)
Loss from continuing operations before income taxes (849) (574)
Income tax provision - current 94 539
Income tax provision - deferred 145 15
Total income taxes provision 239 554
Net loss from continuing operations (1,088) (1,128)
Discontinued operations:    
Income (loss) from discontinued operations, net of tax 128 (501)
Net loss (960) (1,629)
Net loss attributable to noncontrolling interest 34 31
Net loss attributable to Ultralife (926) (1,598)
Other comprehensive income (loss):    
Foreign currency translation adjustments 6 365
Comprehensive income (loss) loss attributable to Ultralife $ (920) $ (1,233)
Net income (loss) attributable to Ultralife common shareholders - basic    
Continuing operations (in Dollars per share) $ (0.06) $ (0.06)
Discontinued operations (in Dollars per share) $ 0.01 $ (0.03)
Total (in Dollars per share) $ (0.05) $ (0.09)
Net income (loss) attributable to Ultralife common shareholders - diluted    
Continuing operations (in Dollars per share) $ (0.06) $ (0.06)
Discontinued operations (in Dollars per share) $ 0.01 $ (0.03)
Total (in Dollars per share) $ (0.05) $ (0.09)
Weighted average shares outstanding - basic (in Shares) 17,465,000 17,403,000
Weighted average shares outstanding - diluted (in Shares) 17,465,000 17,403,000